OpenEvidence alternative · for oncology biotech medical affairs
OpenEvidence is for clinicians. Medical affairs needs a different tool.
UNMIRI · See Literature Intelligence
OpenEvidence is the most-used AI tool in medicine right now. 45% of US physicians use it. $150M ARR in 2025, $12B valuation. It's a phenomenal product for the job it's built for: helping a practicing clinician answer "what should I do for this patient right now" at the bedside, free for verified physicians, monetized via pharma advertising.
That's not the medical affairs job. Medical affairs needs to know "what's happening this week across the literature for our drug + competitive set, what KOLs are publishing on our biomarker, what trials are recruiting, what congresses have abstracts coming." That's surveillance, KOL tracking, competitive landscape. Different tool, different buyer, different model. UNMIRI Engine 3 is for that work.
At a glance
| Dimension | OpenEvidence | UNMIRI |
|---|---|---|
| Primary user | Practicing physicians at point of care | Medical affairs leads, MSLs, CME content directors at oncology biotechs |
| Job to be done | Answer a single clinical question now | Continuous surveillance + KOL tracking + competitive landscape across an oncology drug + competitive set |
| Pricing | Free for verified physicians; pharma ad-supported (~$124 ARPU) | $99/mo individual, $499/mo team, $25-75K enterprise SaaS |
| Output format | Conversational answer in browser, optimized for time-to-decision | Daily/weekly digest, KOL profiles, competitive landscape PDF, watchlist alerts, FHIR / API |
| Scope | All of medicine, all specialties | Oncology-only, variant-stratified |
| MLR / regulatory defensibility | Designed for clinical use, not pharma medical affairs claims | Deterministic templates, reproducibility snapshots, every claim citation-grounded for MLR review |
| Geography | US (now geo-blocked in UK/EU) | US-based, US-only data residency |
Use them together
Many of UNMIRI's prospective customers are medical affairs leads at biotechs whose physicians already use OpenEvidence at the bedside. That's fine — these tools serve different roles. The CMO doesn't replace OpenEvidence with UNMIRI; she adds UNMIRI for the medical affairs work that OpenEvidence isn't built for.
If your CMO has asked "why don't we just use OpenEvidence?" — the honest answer is that your physicians already do, and they should keep using it. Medical affairs needs surveillance, KOL tracking, and landscape outputs that OpenEvidence wasn't designed to produce. UNMIRI is built for that, and the variant-aware oncology graph is what makes the surveillance worth subscribing to.
When OpenEvidence is the right pick
- You are a practicing oncologist asking a point-of-care question about a specific patient.
- You need a fast, conversational answer rather than a continuous monitoring service.
- Your hospital or practice is not paying you to track competitive landscape — you're paid to treat patients.
- You want a free tool with no procurement step.
When UNMIRI is the right pick
- You're medical affairs at a 50-500 person oncology biotech with a drug + four to six competitors to track weekly.
- Your CMO wants a defensible competitive landscape PDF every quarter, with every claim cited to a source the legal team can verify.
- Your MSL team needs KOL profiles ranked by recent publications on the specific variant your drug targets, not by overall publication volume.
- Your medical leadership reviews every digest before it goes to your sales force. The output has to survive MLR.
- You need this content in a format you can paste into a deck or a one-pager, not just a chat conversation.
Frequently asked questions
- Is UNMIRI competing with OpenEvidence?
- Not directly. OpenEvidence answers point-of-care questions for clinicians. UNMIRI runs surveillance, KOL tracking, and competitive landscape work for medical affairs teams. Different buyer, different job, different business model. Many UNMIRI prospects are at biotechs whose physicians already use OpenEvidence at the bedside.
- Can our medical affairs team use OpenEvidence for landscape work?
- It's possible to ask OpenEvidence about a specific topic, but you don't get a continuous filter, KOL profiles ranked by variant-specific recent publications, or a competitive landscape PDF you can share with your sales force. The output format is conversational, not surveillance + report.
- Is OpenEvidence MLR-defensible for our pharma medical affairs claims?
- OpenEvidence was designed for clinical use. Citing OpenEvidence-generated content in pharma medical affairs work requires the same MLR scrutiny as citing any LLM-generated content — you're responsible for verifying every claim against primary sources. UNMIRI's deterministic-template output is designed from the start for that workflow: every claim cites the primary source, and every digest has a reproducibility snapshot you can re-render months later.
- What about the geographic restriction?
- OpenEvidence is geo-blocked in the UK and EU as of 2026. UNMIRI is US-based with US-only data residency. If your medical affairs team is global, OpenEvidence isn't a complete option for non-US users today.
Different tools for different jobs
Your physicians keep using OpenEvidence. Your medical affairs team can spin up an UNMIRI trial in an afternoon. 14-day trial, no credit card.